Physician profile
Derek Towery
NPI 1346237351
$8,234.46
in general payments reported to CMS, 2019-2025
31 companies · $1,509 in 2025
The $1,509 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $972 · 2020: $646 · 2021: $823 · 2022: $1,242 · 2023: $1,542 · 2024: $1,501 · 2025: $1,509.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,237 · Education: $316.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,236.53 |
| Education | $315.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,824.11 | 2019-2025 | Rinvoq, Skyrizi, Humira |
| Janssen Biotech, INC. | $1,337.67 | 2019-2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $731.44 | 2019-2025 | |
| Lilly USA, LLC | $542.68 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Genzyme Corporation | $509.47 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $332.02 | 2022-2024 | Sotyktu |
| Amgen INC. | $298.70 | 2019-2025 | Otezla, Otezla |
| Sun Pharmaceutical Industries INC. | $272.25 | 2019-2025 | Ilumya, Absorica Ld, Winlevi |
| Mayne Pharma Commercial LLC | $268.63 | 2019-2024 | |
| Ucb, INC. | $250.78 | 2019-2025 | Bimzelx |
| Vyne Pharmaceuticals INC. | $183.83 | 2020 | |
| Leo Pharma INC. | $177.32 | 2021-2025 | Adbry |
| Regeneron Healthcare Solutions, INC. | $175.73 | 2019-2024 | Dupixent |
| Celgene Corporation | $157.46 | 2019 | |
| Organogenesis INC. | $153.47 | 2021-2025 | Novachor, Affinity, Puraply |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $148.09 | 2022-2024 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $146.81 | 2019-2024 | Arazlo |
| Genentech USA, INC. | $108.27 | 2019-2022 | |
| Incyte Corporation | $106.77 | 2021-2024 | Opzelura |
| Galderma Laboratories, L.P. | $105.93 | 2019-2025 | Nemluvio |
| Arcutis Biotherapeutics, INC. | $93.94 | 2023-2024 | Zoryve |
| Pfizer INC. | $85.66 | 2019-2025 | |
| Fresenius Kabi USA, LLC | $56.24 | 2023-2024 | Idacio |
| Almirall LLC | $30.73 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.28 | 2023 | Cyltezo |
| Convatec INC. | $26.31 | 2024 | |
| Merck Sharp & Dohme LLC | $24.16 | 2019 | |
| Strata Skin Sciences, INC. | $21.12 | 2025 | Xtrac |
| Helsinn Therapeutics (U.S.), INC. | $12.61 | 2020 | |
| Journey Medical Corporation | $12.35 | 2022 | |
| Prugen, INC. Pharmaceuticals | $11.63 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Derek Towery listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.